Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 1
1945 1
1954 1
1957 1
1961 2
1963 1
1965 3
1968 1
1970 1
1971 3
1973 1
1977 1
1978 1
1979 1
1980 1
1982 4
1983 1
1984 1
1985 1
1986 3
1987 1
1989 5
1990 3
1991 3
1992 2
1993 3
1994 4
1995 4
1996 4
1997 8
1998 9
1999 23
2000 70
2001 55
2002 77
2003 108
2004 120
2005 160
2006 220
2007 245
2008 238
2009 273
2010 322
2011 344
2012 478
2013 561
2014 585
2015 646
2016 691
2017 721
2018 845
2019 965
2020 1055
2021 1200
2022 1211
2023 1151
2024 1100
2025 1187
2026 455

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,582 results

Results by year

Filters applied: . Clear all
Page 1
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.
Percy AK, Neul JL, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, An D, Bishop KM, Youakim JM. Percy AK, et al. Med. 2024 Sep 13;5(9):1178-1189.e3. doi: 10.1016/j.medj.2024.05.018. Epub 2024 Jun 24. Med. 2024. PMID: 38917793 Free article. Clinical Trial.
FINDINGS: Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC were diarrhea (74.7%), vomiting (28.6%), and COVID-19 (11.0%). ...Trofinetide had a similar safety profile in LILAC as in LAVENDER …
FINDINGS: Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC …
Lilac Amirav.
[No authors listed] [No authors listed] Angew Chem Int Ed Engl. 2021 Sep 20;60(39):21098. doi: 10.1002/anie.202109990. Epub 2021 Aug 7. Angew Chem Int Ed Engl. 2021. PMID: 34363309
They have pure unbiased curiosity and chemistry seems to them like magic." Find out more about Lilac Amirav in her Introducing Profile....
They have pure unbiased curiosity and chemistry seems to them like magic." Find out more about Lilac Amirav in her Introducing Prof …
The blooming of the French lilac.
Witters LA. Witters LA. J Clin Invest. 2001 Oct;108(8):1105-7. doi: 10.1172/JCI14178. J Clin Invest. 2001. PMID: 11602616 Free PMC article. Review. No abstract available.
LILAC: enhanced actin imaging with an optogenetic Lifeact.
Kroll KL, French AR, Sosnick TR, Rock RS. Kroll KL, et al. Nat Methods. 2023 Feb;20(2):214-217. doi: 10.1038/s41592-022-01761-3. Epub 2023 Jan 30. Nat Methods. 2023. PMID: 36717692 Free PMC article.
We have designed an improved Lifeact variant, LILAC, that binds to actin in light using the LOV2 protein. Light control allows the user to modulate actin labeling, enabling image analysis that leverages modulation for an enhanced view of F-actin dynamics in cells. ...
We have designed an improved Lifeact variant, LILAC, that binds to actin in light using the LOV2 protein. Light control allows the us …
Clinical pharmacokinetics of metformin.
Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Graham GG, et al. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21241070 Review.
It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). ...
It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hyd …
Lilac (Syringa oblata) genome provides insights into its evolution and molecular mechanism of petal color change.
Ma B, Wu J, Shi TL, Yang YY, Wang WB, Zheng Y, Su SC, Yao YC, Xue WB, Porth I, El-Kassaby YA, Leng PS, Hu ZH, Mao JF. Ma B, et al. Commun Biol. 2022 Jul 9;5(1):686. doi: 10.1038/s42003-022-03646-9. Commun Biol. 2022. PMID: 35810211 Free PMC article.
Color change during flower opening is common; however, little is understood on the biochemical and molecular basis related. Lilac (Syringa oblata), a well-known woody ornamental plant with obvious petal color changes, is an ideal model. ...Our results provide a foun …
Color change during flower opening is common; however, little is understood on the biochemical and molecular basis related. Lilac ( …
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study.
Percy AK, Neul JL, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, Barrett AM, An D, Bishop KM, Youakim JM. Percy AK, et al. Med. 2024 Oct 11;5(10):1275-1281.e2. doi: 10.1016/j.medj.2024.06.007. Epub 2024 Jul 17. Med. 2024. PMID: 39025065 Free article.
Here, we report long-term safety and efficacy results of LILAC-2, a 32-month, open-label extension study. METHODS: Females aged 5-22 years who completed LILAC were eligible to enter LILAC-2. ...The mean (standard error [SE]) change in RSBQ score from LAVENDER …
Here, we report long-term safety and efficacy results of LILAC-2, a 32-month, open-label extension study. METHODS: Females aged 5-22 …
Lilac.
SHUPIS A. SHUPIS A. J Am Inst Homeopath. 1961 Nov-Dec;54:165-6. J Am Inst Homeopath. 1961. PMID: 13912416 No abstract available.
13,582 results
You have reached the last available page of results. Please see the User Guide for more information.